Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Alum-ALM + BCG Vaccine for Cutaneous Leishmaniasis
NCT00429715Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jan 2007
- Primary completion
- May 2007
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of autoclaved leishmania major in cutaneous leishmaniasis (CL), sponsored by Tehran University of Medical Sciences. Primary endpoints: Occurrence of local and/or systemic adverse events and Percentage of volunteers protected against CL. Started Jan 2007; status: completed.
02
Drugs
autoclaved leishmania major
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on NCT00429715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00429715.